Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROFIT: immune responses, inhibitors, and tolerance in hemophilia
NL-OMON48806Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of Factor VIII and coagulation factor ix in hemophilia A and hemophilia B (HB) (3 arms), sponsored by University Medical Center Utrecht. Primary endpoints: Development of inhibitor during first treatment episode, Eradication of inhibitor during immune tolerance induction and 9 more. Started Mar 2019; status: recruiting.
02
Drugs
Factor VIIIcoagulation factor ix
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NL-OMON48806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48806.